Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
144.54B
Market cap144.54B
Price-Earnings ratio
19.59
Price-Earnings ratio19.59
Dividend yield
6.73%
Dividend yield6.73%
Average volume
32.80M
Average volume32.80M
High today
$25.62
High today$25.62
Low today
$25.29
Low today$25.29
Open price
$25.43
Open price$25.43
Volume
30.50M
Volume30.50M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.06
52 Week low$23.06

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $25.37. The company's market cap stands at 144.54B, with a P/E ratio of 19.59 and a dividend yield of 6.7%.

On 2026-06-03, Pfizer(PFE) stock moved within a range of $25.29 to $25.62. With shares now at $25.37, the stock is trading +0.3% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 30.5M, compared to an average daily volume of 32.8M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.06.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.06.

PFE News

TipRanks 4h
Pfizer’s Bevacizumab Biosimilar Safety Study in Japan Reaches Completion: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

TipRanks 4h
Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

24/7 Wall St. 6h
Pfizer vs Merck: Chasing High Yield vs Higher Returns

Pfizer vs Merck: Chasing High Yield vs Higher Returns By Vandita Jadeja Published Jun 3, 10:06AM EDT Quick Read PFE yields 6.58% at a forward P/E of 9, while...

Pfizer vs Merck: Chasing High Yield vs Higher Returns

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

Nasdaq 12h
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?

Key Points Both are working hard to get around patent cliffs. One of them seems to have made more progress on that front. 10 stocks we like better than Brist...

Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
24/7 Wall St. 1d
Why Pfizer’s Current Price May Be Too Cheap to Ignore

Why Pfizer’s Current Price May Be Too Cheap to Ignore By Vandita Jadeja Published Jun 2, 10:03AM EDT Quick Read Pfizer (PFE) trades at $26.18 with a 24/7 Wall...

Why Pfizer’s Current Price May Be Too Cheap to Ignore
Simply Wall St 1d
Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story

Pfizer reported new seven-year data from the Phase 3 CROWN trial at ASCO 2026, highlighting LORBRENA for untreated ALK-positive advanced non small cell lung can...

Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story
Nasdaq 2d
Pfizer Shares Cross Below 200 DMA

In trading on Monday, shares of Pfizer Inc (Symbol: PFE) crossed below their 200 day moving average of $25.83, changing hands as low as $25.48 per share. Pfizer...

Pfizer Shares Cross Below 200 DMA
Nasdaq 2d
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Key Points AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue. Pfizer maintains a diverse portfolio...

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Nasdaq 2d
Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?

Key Points Pfizer could flourish under a Warsh-led Fed for several reasons. However, the drugmaker won't be a slam-dunk winner, in part because of its debt an...

Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?
TipRanks 3d
Analyst Maintains Hold on Pfizer, Keeps Price Target Unchanged at $27 Amid Pipeline Uncertainties

UBS analyst Michael Yee has maintained their neutral stance on PFE stock, giving a Hold rating on May 28. Unlock trusted, data-backed investing tools with TipR...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.